Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus PT from Analysts

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have been given a consensus rating of “Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $18.33.

INZY has been the subject of a number of research analyst reports. HC Wainwright raised their target price on Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, January 10th. Wells Fargo & Company lowered their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday, November 6th. Piper Sandler dropped their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Finally, Wedbush reaffirmed an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a research report on Friday, January 10th.

Inozyme Pharma Price Performance

Shares of INZY opened at $1.09 on Friday. The stock has a market cap of $70.02 million, a PE ratio of -0.70 and a beta of 1.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a 1-year low of $1.09 and a 1-year high of $7.80. The firm has a 50-day simple moving average of $1.80 and a two-hundred day simple moving average of $3.49.

Institutional Trading of Inozyme Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in INZY. Affinity Asset Advisors LLC increased its position in Inozyme Pharma by 40.7% during the fourth quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company’s stock worth $11,003,000 after buying an additional 1,150,000 shares during the period. Sanofi purchased a new stake in Inozyme Pharma in the 4th quarter valued at $1,228,000. Renaissance Technologies LLC grew its position in Inozyme Pharma by 155.7% during the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company’s stock worth $1,167,000 after purchasing an additional 256,599 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Inozyme Pharma in the fourth quarter valued at about $658,000. Finally, Eventide Asset Management LLC grew its holdings in shares of Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after buying an additional 198,216 shares during the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.